Viva Biotech Holdings's gross profit for the
six
months ended in Jun. 2024 was HK$365 Mil. Viva Biotech Holdings's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was HK$737 Mil.
Viva Biotech Holdings gross margin has been in long-term decline. The average rate of decline per year is -9%.
Viva Biotech Holdings Gross Profit Historical Data
The historical data trend for Viva Biotech Holdings's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viva Biotech Holdings's Gross Profit
For the Biotechnology subindustry, Viva Biotech Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Gross Profit distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$737 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Viva Biotech Holdings had a gross margin of 34.54% for the quarter that ended in Jun. 2024 => Competition eroding margins
Viva Biotech Holdings Gross Profit Related Terms
Thank you for viewing the detailed overview of Viva Biotech Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01873 has been successfully added to your 